indazoles has been researched along with bosentan anhydrous in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Chen, Y; Du, G; Fang, L; Niu, Z; Yuan, T; Zhang, H | 1 |
1 other study(ies) available for indazoles and bosentan anhydrous
| Article | Year |
|---|---|
DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bosentan; Disease Models, Animal; Hypertension, Pulmonary; Indazoles; Male; Monocrotaline; Nitriles; Protein Kinase Inhibitors; Pulmonary Artery; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Vasodilator Agents | 2022 |